Disease-Modifying Antirheumatic Drugs in Children With Juvenile Idiopathic Arthritis
Controlled Studies in This CER: Adding Nonbiologic DMARDs to Conventional Anti-inflammatory Drugs (2 of 2)
There are a few studies of a few patients that specifically investigated the use of DMARDs in JIA. The DMARDs studied, the number of trials, the comparators and other interventions allowed, and the characteristics of the study population (number of patients with each category of disease at onset) are listed here.
Three studies of methotrexate were reviewed:
In one study, the comparison group was allowed NSAIDs and methylprednisolone. The study population included 63 patients with JIA (subtype undefined).
A second study of 127 patients with JIA compared methotrexate with a placebo and permitted NSAIDs and methylprednisolone.
The third study compared methotrexate with a placebo and permitted the use of NSAIDs, prednisolone, and intra-articular corticosteroids. The study population included 43 patients with extended oligoarticular disease and 45 with systemic disease at onset.
Keywords: juvenile idiopathic arthritis | JIA | JRA | juvenile rheumatic arthritis | JCA | juvenile chronic arthritis | DMARDs | disease-modifying | antirheumatic | anti-rheumatic | rheumatic | biologic | nonbiologic | non-biologic | methotrexate
- Kemper A, Coeytaux R, Sanders G, et al. Disease-Modifying Antirheumatic Drugs (DMARDs) in Children With Juvenile Idiopathic Arthritis (JIA). Comparative Effectiveness Review No. 28 (Prepared by the Duke Evidence-based Practice Center under Contract No. HHSA 290-2007-10066-I). Rockville, MD: Agency for Healthcare Research and Quality; September 2011. AHRQ Publication No. 11-EHC039-EF. Available at www.effectivehealthcare.ahrq.gov/dmardsjia.cfm.
Your slide tray is being processed.